Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Lymphoma or Advanced Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00861965
What this trial is testing

Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers

Who this might be right for
Advanced or Refractory Leukemia, Lymphoma, Multiple Myeloma
Mirror Biologics, Inc. 2
Early research (Phase 1)Ended earlyNCT00301769
What this trial is testing

SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)+11 more
National Cancer Institute (NCI) 25
Early research (Phase 1)Study completedNCT04306224
What this trial is testing

IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

Who this might be right for
Solid TumorLymphoma
ImmuneOncia Therapeutics Inc. 12
Early research (Phase 1)Study completedNCT06082596
What this trial is testing

Study of BEBT-908 in Subjects With Advanced Hematological Tumors

Who this might be right for
Relapsed or Refractory Non-Hodgkin's LymphomaRelapsed or Refractory Multiple Myeloma
BeBetter Med Inc 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT03210714
What this trial is testing

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent Childhood EpendymomaRecurrent Childhood Malignant Germ Cell Tumor+29 more
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Ended earlyNCT03323398
What this trial is testing

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Who this might be right for
Relapsed/Refractory Solid Tumor Malignancies or LymphomaOvarian Cancer
ModernaTX, Inc. 79
Early research (Phase 1)Ended earlyNCT04553692
What this trial is testing

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Who this might be right for
Solid TumorColorectal CancerNon Hodgkin Lymphoma+5 more
IGM Biosciences, Inc. 272
Testing effectiveness (Phase 2)Study completedNCT00132028
What this trial is testing

Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma

Who this might be right for
Adult Favorable Prognosis Hodgkin LymphomaAdult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin Lymphoma+5 more
National Cancer Institute (NCI) 27
Early research (Phase 1)Ended earlyNCT02408861
What this trial is testing

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Who this might be right for
Advanced Malignant Solid NeoplasmAnal CarcinomaHIV Infection+7 more
National Cancer Institute (NCI) 79
Testing effectiveness (Phase 2)Ended earlyNCT02089230
What this trial is testing

MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 19
Early research (Phase 1)Study completedNCT00006040
What this trial is testing

Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Study completedNCT03934814
What this trial is testing

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Who this might be right for
Solid TumorLymphoma
I-Mab Biopharma US Limited 98
Early research (Phase 1)Study completedNCT03884556
What this trial is testing

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Who this might be right for
Solid TumorLymphoma
Trishula Therapeutics, Inc. 56
Early research (Phase 1)UnknownNCT03510767
What this trial is testing

TQ-B3525 on Tolerance and Pharmacokinetics

Who this might be right for
Relapsed or Refractory Lymphoma or Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 60
Early research (Phase 1)Study completedNCT01164709
What this trial is testing

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMature T-cell and Nk-cell Neoplasms+1 more
Swiss Cancer Institute 18
Early research (Phase 1)Looking for participantsNCT07603479
What this trial is testing

JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Who this might be right for
MalignanciesSolid Malignant TumorNHL (Non-Hodgkin Lymphoma)+1 more
Jecho Biopharmaceuticals Co., Ltd. 14
Testing effectiveness (Phase 2)Study completedNCT03526250
What this trial is testing

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmRecurrent Childhood EpendymomaRecurrent Ewing Sarcoma+29 more
National Cancer Institute (NCI) 23
Early research (Phase 1)Study completedNCT04681105
What this trial is testing

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Who this might be right for
Recurrent Acute LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent Blastic Plasmacytoid Dendritic Cell Neoplasm+14 more
City of Hope Medical Center 13
Testing effectiveness (Phase 2)Ended earlyNCT04504708
What this trial is testing

Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

Who this might be right for
Non-hodgkin LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Hangzhou Zenshine Pharmaceuticals Co., Ltd. 6
Testing effectiveness (Phase 2)UnknownNCT04405375
What this trial is testing

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Who this might be right for
Extranodal NK/T-cell Lymphoma, Nasal Type
Beijing Tongren Hospital 29
Next Page